Suat Kılıç1, Sarah S Kılıç2, Wayne D Hsueh1, Jean Anderson Eloy1,3,4,5, Soly Baredes1,3, Richard Chan Woo Park1, Omar Mahmoud2. 1. Department of Otolaryngology, Head and Neck Surgery, Rutgers New Jersey Medical School, Newark, New Jersey. 2. Department of Radiation Oncology, Rutgers New Jersey Medical School, Newark, New Jersey. 3. Center for Skull Base and Pituitary Surgery, Neurological Institute of New Jersey, Rutgers New Jersey Medical School, Newark, New Jersey. 4. Department of Neurological Surgery, Rutgers New Jersey Medical School, Newark, New Jersey. 5. Department of Ophthalmology and Visual Science, Rutgers New Jersey Medical School, Newark, New Jersey.
Abstract
BACKGROUND: The impact of radiotherapy (RT) modality and dose on survival in hypopharyngeal cancer managed with definitive RT is unclear. METHODS: The National Cancer Database was queried for patients with hypopharyngeal squamous cell carcinoma (HPSCC) treated with definitive RT. Intensity-modulated radiotherapy (IMRT) was compared with other RT techniques. Clinicopathologic variables, RT modality, and dose impact on overall survival (OS) were assessed using log-rank test and Cox proportional hazard models. RESULTS: A total of 3928 patients with HPSCC were identified. Patients receiving IMRT (2098 patients) were more likely to be white, have higher income, have advanced classification, receive ≥66 Gy, and receive chemoradiotherapy compared with those receiving non-IMRT techniques (1830 patients). The 5-year OS was 41.9% (95% CI = 39.4%-44.4%) for the IMRT group and 36.8% for the non-IMRT group (95% CI = 34.3%-39.2%). After propensity score matching, IMRT had significantly better OS (P = .013). CONCLUSION: In HPSCC treated with definitive RT, IMRT may provide a significant survival benefit over non-IMRT modalities.
BACKGROUND: The impact of radiotherapy (RT) modality and dose on survival in hypopharyngeal cancer managed with definitive RT is unclear. METHODS: The National Cancer Database was queried for patients with hypopharyngeal squamous cell carcinoma (HPSCC) treated with definitive RT. Intensity-modulated radiotherapy (IMRT) was compared with other RT techniques. Clinicopathologic variables, RT modality, and dose impact on overall survival (OS) were assessed using log-rank test and Cox proportional hazard models. RESULTS: A total of 3928 patients with HPSCC were identified. Patients receiving IMRT (2098 patients) were more likely to be white, have higher income, have advanced classification, receive ≥66 Gy, and receive chemoradiotherapy compared with those receiving non-IMRT techniques (1830 patients). The 5-year OS was 41.9% (95% CI = 39.4%-44.4%) for the IMRT group and 36.8% for the non-IMRT group (95% CI = 34.3%-39.2%). After propensity score matching, IMRT had significantly better OS (P = .013). CONCLUSION: In HPSCC treated with definitive RT, IMRT may provide a significant survival benefit over non-IMRT modalities.
Authors: Maryam Gul; Kimberley-Jane C Bonjoc; David Gorlin; Chi Wah Wong; Amirah Salem; Vincent La; Aleksandr Filippov; Abbas Chaudhry; Muhammad H Imam; Ammar A Chaudhry Journal: Front Oncol Date: 2021-07-07 Impact factor: 6.244